NCT05241535 is a Phase 1 clinical trial of MT-7117 in Healthy Subjects, sponsored by Tanabe Pharma America, Inc..

Who is sponsoring NCT05241535?

NCT05241535 is sponsored by Tanabe Pharma America, Inc..

What drugs are being tested in NCT05241535?

Interventions in NCT05241535: MT-7117, moxifloxacin, Placebo.

What condition does NCT05241535 study?

NCT05241535 studies Healthy Subjects.

Is NCT05241535 still recruiting?

NCT05241535 is currently completed. Last updated 15 May 2023.

Last reviewed 2023-05-15 · How we verify

NCT05241535

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study to Evaluate the Effect of a Single Oral Dose of MT-7117 on the QT/QTc Interval in Healthy Subjects

Completed Phase 1 Last updated 15 May 2023

What this trial tests

Phase 1 trial testing MT-7117 in Healthy Subjects in 29 participants. Completed in 27 February 2022.

Timeline

12 January 2022

Primary endpoint
23 February 2022

27 February 2022

Quick facts

Lead sponsor	Tanabe Pharma America, Inc.
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	quadruple
Primary purpose	other
Enrollment	29
Start date	12 January 2022
Primary completion	23 February 2022
Estimated completion	27 February 2022
Sites	2 locations across United States

Drugs / interventions tested

MT-7117 — full drug profile →
moxifloxacin (moxifloxacin) — full drug profile →
Placebo

Conditions studied

Healthy Subjects — all drugs for Healthy Subjects →

Sponsor

Tanabe Pharma America, Inc. — full company profile →

Who can join

Adults 18 to 45, any sex, with Healthy Subjects. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to evaluate the effect of a single oral dose of MT-7117 on the QT/QTc interval in healthy subjects.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of MT-7117

Trials testing the same drug.

NCT06994286 — The Purpose of This Study is to Investigate the Safety, Tolerability and Pharmacokinetics of MT-7117 in Healthy Subjects · Phase 1 · completed
NCT04793295 — Study to Investigate Drug-Drug Interaction Between MT-7117 and Test Drugs in Healthy Subjects · Phase 1 · completed
NCT04440592 — Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Diffuse Cutaneous Systemic Sclerosis · Phase 2 · completed
NCT04656795 — PK Study in Subjects With Renal Impairment (Severe and if Required Mild & Moderate) Compared to Subjects With Normal Ren · Phase 1 · completed
NCT04116476 — Study to Assess Pharmacokinetics, Safety, and Tolerability of MT-7117 in Subjects With Normal and Impaired Hepatic Funct · Phase 1 · completed

Other recruiting trials for Healthy Subjects

Currently open trials in the same condition.

NCT07222020 — Phase 1 Study of Intravaginal KB15A · Phase 1 · recruiting
NCT07350538 — The Critical Link Between Gut Microbiome Dysfunction, Cravings and Relapse: RECLAIM-GUT TRIAL · NA · active not recruiting
NCT07304791 — This is a Phase 1, Randomized, Single-blind, Placebo-controlled Study to Assess the Safety, Pharmacokinetics (PK), and P · Phase 1 · recruiting
NCT07059858 — Bladder and Bowel Functions, Participation and Quality of Life in Children With Intellectual Disabilities · recruiting
NCT07331389 — A Drug-Drug Interaction Study of HDM1002 and Metformin, Empagliflozin, Midazolam, Valsartan, and Warfarin · Phase 1 · recruiting

Other Tanabe Pharma America, Inc. trials

Trials by the same sponsor.

NCT05151471 — Efficacy and Safety Extension Study of Oral Edaravone Administered in Subjects With ALS · Phase 3 · terminated
NCT04683848 — Study to Assess the Efficacy and Safety of MT-3921 in Subjects With Acute Traumatic Cervical Spinal Cord Injury · Phase 2 · completed
NCT04793295 — Study to Investigate Drug-Drug Interaction Between MT-7117 and Test Drugs in Healthy Subjects · Phase 1 · completed
NCT04440592 — Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Diffuse Cutaneous Systemic Sclerosis · Phase 2 · completed
NCT04656795 — PK Study in Subjects With Renal Impairment (Severe and if Required Mild & Moderate) Compared to Subjects With Normal Ren · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05241535 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Tanabe Pharma America, Inc.
Last refreshed: 15 May 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05241535.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing